These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
114 related items for PubMed ID: 21934349
1. Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study. Roth A, Schleyer E, Schoppmeyer K, Kluge R, Wittekind C, Mössner J, Wiedmann M. Onkologie; 2011; 34(8-9):469-70. PubMed ID: 21934349 [No Abstract] [Full Text] [Related]
10. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Wiedmann M, Caca K, Berr F, Schiefke I, Tannapfel A, Wittekind C, Mössner J, Hauss J, Witzigmann H. Cancer; 2003 Jun 01; 97(11):2783-90. PubMed ID: 12767091 [Abstract] [Full Text] [Related]
11. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location. Song BG, Park JK, Kim HS, Kim K, Park JK, Lee KH, Lee KT, Lee JK. Scand J Gastroenterol; 2019 Jun 01; 54(6):740-745. PubMed ID: 31136212 [Abstract] [Full Text] [Related]
12. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Clin Cancer Res; 2006 Aug 15; 12(16):4899-907. PubMed ID: 16914578 [Abstract] [Full Text] [Related]
13. Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil. Silveira CA, Daldegan MB, Ferrari I. Genet Mol Res; 2011 Sep 15; 10(3):2038-48. PubMed ID: 21968620 [Abstract] [Full Text] [Related]
14. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor]. Shen L, Jin ML. Zhonghua Zhong Liu Za Zhi; 2004 Nov 15; 26(11):697-9. PubMed ID: 15777512 [Abstract] [Full Text] [Related]
17. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Mathy A, Baas P, Dalesio O, van Zandwijk N. Lung Cancer; 2005 Oct 15; 50(1):83-6. PubMed ID: 15951053 [Abstract] [Full Text] [Related]
19. Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country. Aziz Z, Iqbal J, Bano K, Faisal M, Akram M. Jpn J Clin Oncol; 2010 Jun 15; 40(6):549-55. PubMed ID: 20189974 [Abstract] [Full Text] [Related]
20. Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice. Kamenz T, Caca K, Blüthner T, Tannapfel A, Mössner J, Wiedmann M. World J Gastroenterol; 2006 Mar 14; 12(10):1583-90. PubMed ID: 16570351 [Abstract] [Full Text] [Related] Page: [Next] [New Search]